Skip directly to content

Rapamune® (sirolimus)

What is Rapamune® (sirolimus) and what is it used for?

Rapamune contains the active substance sirolimus, which belongs to a group of medicines called immunosuppressants. It is available as an oral solution and as tablets.

It helps to control your body’s immune system after you have received a kidney transplant.

Rapamune is used in adults, aged 18 years or over, to prevent the rejection of transplanted kidneys and is normally used with other immunosuppressant medicines called corticosteroids and initially (the first 2 to 3 months) with ciclosporin.

Rapamune works by reducing the number of activated T-lymphocytes (white blood cells that are responsible for attacking the transplanted organ), which reduces the risk of organ rejection.

Rapamune is for oral use only.

The medicine can only be obtained with a prescription.
 

Reference information
  • The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU), located in London. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies for use in the EU. See what guidance they offer about Rapamune.
  • If you would like to see the Patient Information Leaflet or Summary of Product Characteristics for Rapamune these can be found at the electronic Medicines Compendium (eMC).
PP-RAP-GBR-0003 / Oct 2017

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professionals for specific, health-related advice and support.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse.. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.